TOLERABILITY AND EFFECTIVENESS OF CPC111 IN SICKLE CELL ANEMIA

CPC111 在镰状细胞贫血症中的耐受性和有效性

• 批准号: 6274035
• 负责人: WENDELL F ROSSE
• 金额: $ 2.88万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274035
• 关键词: blood disorder chemotherapy; clinical research; clinical trials; drug screening /evaluation; fructose biphosphatase; human subject; human therapy evaluation; intravenous administration; sickle cell anemia; sickle cell crisis

The purpose of this study is to evaluate the tolerability and effectiveness of intravenous fructose diphosphate (FDP) in patients in acute sickle cell crisis. FDP provides 4 moles of ATP to the cell for every molecule of glucose that is anaerobically metabolized. It is felt that the increased available energy will help the red blood cell resist sickling and as a result shorten the duration of the pain crisis. The GCRC is requested for infusions of the study drug or placebo every 6 hours over 72 hours. There will be a total of 96 patients evaluated over 4 study centers. The primary hypothesis will focus on the reduction of pain at 24 hours after the first infusion. The study is ongoing. There are no results to report at this time.

本研究的目的是评估耐受性和 静脉注射果糖二磷酸（FDP）对以下患者的有效性 急性镰状细胞危象。 FDP 为细胞提供 4 摩尔 ATP 无氧代谢的每个葡萄糖分子。 是感觉到的 增加的可用能量将有助于红细胞抵抗 镰状化，从而缩短疼痛危机的持续时间。 这 GCRC 要求每 6 小时输注一次研究药物或安慰剂 超过72小时。 4 天内总共将评估 96 名患者 学习中心。 主要假设将集中于减轻疼痛 第一次输注后 24 小时。 该研究正在进行中。 没有 此时报告结果。